Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Corporate Update on Q4 2023 Financial Results
Summary
On January 8, 2024, Regeneron Pharmaceuticals provided a corporate update on its preliminary fourth quarter 2023 financial results at the 42nd Annual J.P. Morgan Healthcare Conference. The company reported U.S. net product sales of approximately $123 million for EYLEA HD (aflibercept) Injection 8 mg and $1.34 billion for EYLEA (aflibercept) Injection. Regeneron expects to record an acquired in-process research and development charge of $30 million, negatively impacting GAAP and non-GAAP net income per diluted share by approximately $0.21. This charge relates to extending the collaboration with Intellia Therapeutics. These results are preliminary and subject to change.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement